Fractyl Health, Inc.’s (NASDAQ:GUTS) Lock-Up Period To Expire Tomorrow

Fractyl Health’s (NASDAQ:GUTS) lock-up period will expire on Wednesday, July 31st. Fractyl Health had issued 7,333,333 shares in its public offering on February 2nd. The total size of the offering was $109,999,995 based on an initial share price of $15.00. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Fractyl Health Price Performance

Shares of Fractyl Health stock opened at $4.09 on Tuesday. The company has a 50-day moving average price of $5.32. Fractyl Health has a fifty-two week low of $3.77 and a fifty-two week high of $14.50. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.38 and a quick ratio of 9.37.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.45). The firm had revenue of $0.03 million during the quarter. On average, equities analysts forecast that Fractyl Health will post -2.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

A hedge fund recently bought a new stake in Fractyl Health stock. American International Group Inc. acquired a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,339,261 shares of the company’s stock, valued at approximately $9,911,000. American International Group Inc. owned 2.80% of Fractyl Health at the end of the most recent quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.